Brought to you by 
Abgenix and Pfizer sign antibody generation deal
29 Jun 2005
Executive Summary
Cell Genesys subsidiary Abgenix (monoclonal antibodies) signed a worldwide agreement to generate human antibodies for up to three undisclosed antigen targets for Pfizer, using its XenoMouse technology.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Transgenics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com